DLBCL
From the Journals
Race and location appear to play a role in the incidence of CLL and DLBCL
From the Journals
DLBCL patients at academic centers had significantly better survival
Researchers suggested that academic centers might provide increased access to clinical trials, improved physician expertise, improved treatment...
From the Journals
Safer CAR uses modified NK cells for advanced CLL, NHL
From the Journals
DLBCL tops cases of HBV-associated NHL in Europe
Conference Coverage
REGN1979 shows good activity in pretreated aggressive B-NHL
...
Guidelines
NCCN guidelines highlight ‘complicated’ treatment for pediatric lymphomas
The guidelines include recommendations for managing pediatric Burkitt lymphoma and diffuse large B-cell lymphoma.
Conference Coverage
Survival data reported from largest CAR T trial in B-cell lymphoma
ORLANDO – Progression-free survival results were best among complete responders and patients with primary mediastinal large B-cell lymphoma or...
Conference Coverage
Care coordination, equity can eliminate disparities for nonwhite patients with DLBCL
The use of a nurse navigation program to facilitate care helped iron out racial disparities that could lead to poor outcomes.
From the Journals
Adding polatuzumab extends survival in relapsed/refractory DLBCL
The combination offers a viable alternative for a group of patients with historically “dismal” outcomes, investigators said.
Conference Coverage
Armored CAR T cells elicit responses in NHL patients
NATIONAL HARBOR, MD. – ICTCAR014, a dominant negative PD-1 armored CAR T-cell therapy, produced responses in 12 of 13 non-Hodgkin lymphoma...
From the Journals
CAR T-cell therapy found safe, effective for HIV-associated lymphoma
Two HIV-positive patients with chemotherapy-refractory, high-grade B-cell lymphoma achieved complete remission with anti-CD19 CAR T-cell therapy,...